Stocktoria

Transcode Therapeutics, Inc. RNAZ

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2021-04-28

Transcode Therapeutics, Inc. statistics & valuation

Market cap$4.7M
P / B0.5×
Return on capital-17.6%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
202020212022202320242025
Operating margin (%)
202020212022202320242025
Return on equity (%)
-33.50% -542.00% -1130.30% -335.40% 202020212022202320242025
Shares outstanding
4.6M 12.9M 16222 19014 36753 916968 202020212022202320242025
Net debt ($)
202020212022202320242025
Share buybacks ($)
202020212022202320242025
Return on assets (%)
-222.10% -29.80% -231.50% -358.70% -229.70% -21.30% 202020212022202320242025
Free cash flow margin (%)
202020212022202320242025
Debt / equity (×)
202020212022202320242025
EPS ($)
-$0.51 -$0.81 -$1082.79 -$3419.01 -$1336.63 -$52.59 202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020
Return on assets-21.3%-229.7%-358.7%-231.5%-29.8%-222.1%
Return on equity-335.4%830.0%-1130.3%-542.0%-33.5%68.8%
Current ratio6.292.561.281.708.972.05

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.